Biobeat logo

Biobeat

The first FDA-cleared, cuffless 24-hour ambulatory blood pressure monitoring system, enabling accurate hypertension diagnosis and chronic disease management through a patch-worn wearable.

Data & Analytics Growth Series B
Visit Website

Overview

Biobeat is an Israeli medical technology company that developed the first FDA-cleared, cuffless 24-hour ambulatory blood pressure monitoring (ABPM) system. Founded in 2016 by CEO Arik Ben Ishay and co-founders Johanan May and Israel Sarussi, the company's disposable chest patch device delivers continuous, non-invasive vital signs monitoring without the discomfort of traditional cuff-inflation cycles -- enabling uninterrupted sleep monitoring and eliminating white-coat syndrome artifacts.

The platform has received multiple FDA clearances and CE marking, and is validated against gold-standard cuff-based monitoring with findings published in the American Journal of Hypertension. In December 2025, Biobeat closed a USD 50 million Series B round led by Ally Bridge Group, OrbiMed Advisors, and Elevage Medical, bringing total funding to approximately USD 71.8 million. The company established a U.S. hub in Boca Raton, Florida in 2024 and is actively expanding its U.S. commercial sales operation.

Biobeat's remote patient monitoring platform connects directly to health insurers' value-based care programs, providing the clinical-grade ambulatory data required for hypertension diagnosis, chronic disease management, and reimbursable RPM services under Medicare and commercial payer guidelines.

Products & Services

Chest Patch ABPM Monitor

A disposable, short-term chest patch for 24-hour ambulatory blood pressure monitoring. FDA-cleared (K190792, K181006, K212153, K222010, K241066) and CE marked (2797). Validated against gold-standard cuff-based devices and published in peer-reviewed literature.

Key Features

  • Cuffless, continuous blood pressure measurement over 24 hours
  • Eliminates white-coat syndrome and masked hypertension artifacts
  • Uninterrupted nighttime monitoring without patient sleep disruption
  • Automatic clinical report generation for care providers
  • ACC/AHA guideline-supported ambulatory monitoring methodology

Target Users: Cardiologists, hypertension specialists, primary care physicians, health systems

Wrist Monitor

A long-term wrist-worn device using PPG sensors for continuous measurement of 13 hemodynamic and vital parameters including blood pressure, SpO2, cardiac output, and respiratory rate.

Key Features

  • Continuous multi-parameter vital signs monitoring
  • Long-term wear for chronic disease management
  • AI-driven Early Warning Score (EWS) alerts
  • HIPAA and GDPR-compliant cloud transmission

Target Users: Chronic disease management programs, hospital-at-home, post-acute care

Remote Patient Monitoring Platform

Cloud-connected platform with mobile app integration, automated clinical report generation, and AI analytics. Supports reimbursable RPM workflows under CMS CPT codes (e.g., 99453, 99454).

Key Features

  • Real-time data transmission to mobile app and care team dashboard
  • Automated Early Warning Score with AI-based clinical alerts
  • HIPAA and GDPR compliant
  • Integration with clinical workflows for hypertension diagnosis and chronic disease management

Target Users: Health systems, payers, employers running value-based care programs

At a Glance

Founded
2016
Headquarters
Petah Tikva, Israel (U.S. hub: Boca Raton, Florida)
Employees
11-50
Funding
Series B

Category & Focus

Category
Data & Analytics
Subcategories
Remote patient monitoring wearable health tech ambulatory blood pressure monitoring vital signs monitoring
Insurance Verticals
Health Group Benefits
Target Customers
Carriers, Employers, Consumers

Customers

  • Hackensack Meridian Health (HMH Emerge Program 2026 partner)
  • Kestra Medical Technologies (strategic partnership for wearable defibrillator patients)

Last updated: 2026-05-11